Nektar Therapeutics (NKTR) Consolidated Net Income (2010 - 2026)

Nektar Therapeutics' Consolidated Net Income history runs 17 years deep, the most recent figure standing at -$43.2 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income rose 7.04% year-over-year to -$43.2 million in Q1 2026; TTM through Mar 2026 was -$117.7 million, a 13.44% decrease from a year earlier, with the FY2025 full-year figure at -$121.0 million, down 28.5% from the prior year.
• Consolidated Net Income declined to -$43.2 million in Q1 2026 per NKTR's latest filing, from -$386000.0 in the prior quarter.
• Across five years, Consolidated Net Income topped out at $32.1 million in Q4 2024 and bottomed at -$159.1 million in Q2 2022.
• The 5-year median for Consolidated Net Income is -$43.2 million (2026), against an average of -$48.4 million.
• Across the five-year window, Consolidated Net Income tumbled 308.58% in 2023 and soared 176.18% in 2024, its largest moves.
• Year by year, Consolidated Net Income stood at $20.2 million in 2022, then tumbled by 308.58% to -$42.1 million in 2023, then jumped by 176.18% to $32.1 million in 2024, then slumped by 101.2% to -$386000.0 in 2025, then tumbled by 11079.79% to -$43.2 million in 2026.
• Per Business Quant, the three latest NKTR Consolidated Net Income figures stand at -$43.2 million (Q1 2026), -$386000.0 (Q4 2025), and -$35.0 million (Q3 2025).